is semaglutide in short supply shortage ends as FDA sets deadline for compounders FDA says Ozempic, Wegovy are

1998 Jun 15;103(2):123-32

We had assumed it was a consequence of losing weight but this seems to suggest theres a separate pathway. We dont know how those effects would play out in patients at a healthy weight, because they werent part of the study so it doesnt mean that semaglutides should be considered as a treatment for anyone with heart issues regardless of their weight

Reports circulating in early 2026 of a broad move of Category 2 peptides back toward Category 1, and specific vendor claims that BPC-157 was "removed" from Category 2 in April 2026, could not be confirmed from an authoritative FDA source and are not treated as fact here

PMID: 39621418

Theyre step-by-step journeys

The medication is widely prescribed for diabetic neuropathy and peripheral neuropathy due to its ability to repair and protect nerves